SLC25A1 and B-cell chronic lymphocytic leukemia: To confirm this analysis and explore potential novel biomarkers for CLL progression, we examined the expression level of DHRS4, SLC25A1, and UBE3A in PBMCs from groups A and B by immunoblotting using specific antibodies (Fig 7C).